Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2002754 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells.
Front Immunol
December 2024
Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg-University (JGU) Medical Center, Mainz, Germany.
Background: The insulin-like growth factor 1 receptor (IGF-1R) and the thyrotropin receptor (TSH-R) are expressed on orbital cells and thyrocytes. These receptors are targeted in autoimmune-induced thyroid eye disease (TED). Effective therapeutic treatment of TED inhibits activation of the IGF-1R/TSH-R complex.
View Article and Find Full Text PDFEfficacy, Safety, and Recurrence in Older Thyroid Eye Disease Patients Undergoing Teprotumumab Treatment.
Ophthalmic Plast Reconstr Surg
December 2024
Israel Englander Department of Ophthalmology, Weill Cornell Medical College, New York City, New York, U.S.A.
Increasing life expectancy and an aging population have preserved quality of life decisions into older adulthood, defined by some clinical standards as greater than 75 years of age. While teprotumumab may represent a breakthrough in the treatment of thyroid eye disease, the teprotumumab phase III trial included only 2 patients aged over 75. Four female patients between the ages of 78 and 86-of whom 3 completed 8 infusions and 1 completed 7 infusions before discontinuation-were included in our study with a mean initial Clinical Activity Score score of 5.
View Article and Find Full Text PDFComprehensive Comparisons of Different Treatments for Active Graves' Orbitopathy: A Systematic Review and Bayesian Model-Based Network Meta-Analysis.
J Clin Endocrinol Metab
December 2024
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Objective: This study aims to assess the efficacy and safety of various treatments for active thyroid eye disease.
Method: We conducted a comprehensive search for randomized controlled trials (RCTs), and ongoing RCTs registered on Controlled Trials, targeting treatments for thyroid eye disease up until November 20, 2024. Employing a Bayesian framework, this network meta-analysis calculated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) to size the effects for the predetermined outcomes.
Surgical Timing for Patients with Thyroid Eye Disease Treated with Teprotumumab: A Collaborative Multicenter Study.
Ophthalmic Plast Reconstr Surg
December 2024
Department of Oculofacial Plastic Surgery, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.
Purpose: To compare regression rates, characteristics, and surgical outcomes of thyroid eye disease patients who underwent orbit, strabismus, or eyelid surgery at various times during or after teprotumumab treatment.
Design: Multicenter, retrospective, observational cohort study.
Participants: Adult patients (age >18) with a minimum of 4 infusions of teprotumumab treatment for thyroid eye disease who had had eye surgery during or after treatment.
Teprotumumab's Impact on Proptosis in Long-duration Thyroid Eye Disease: A Systematic Review and Meta-analysis.
touchREV Endocrinol
October 2024
Ophthalmology, School of Medicine, Lubbock Campus, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Long-duration thyroid eye disease (TED) may present with persistent proptosis despite the absence of inflammatory symptoms, and treatment options have been limited to surgical intervention. Recently, teprotumumab, a monoclonal antibody, has garnered interest as a non-surgical option to reduce proptosis in such cases. This systematic review investigates the impact of teprotumumab on reducing proptosis in long-duration TED.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!